Skip to content
DataLookout
Menu

MIA-COMPNCT07758140

Comparative Self-collection for Cervical Cancer Screening Pivotal Study

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 14 words
    • Primary and study completion dates pushed to Dec 2026
    • Site details revised at 1 of 11 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Rate of Severe Adverse Events
Timeframe: Between 6 and 14 days.
Negative Percent Agreement (NPA) and Positive Percent Agreement (PPA)
Timeframe: Within one week of sample collection.

Arms and interventions

General Population GroupActive comparator

1. Participants are 25 to 65 years of age and willing to provide informed consent. 2. Participants have an intact cervix.

Enriched Population GroupActive comparator

1. Participants are 25 to 65 years of age and willing to provide informed consent. 2. Participants have an intact cervix. 3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention.

Diagnostic tests: Mia by XytoTest, Rovers Cervex-Brush

Sites

11 sites in 1 country